AbbVie (ABBV) executive compensation, 2026 proxy

Robert A. Michael, Chairman of the Board and Chief Executive Officer, was paid $32.5M in 2025, up 76% from $18.5M the year before. The CEO-to-median-employee pay ratio was 192:1.

Filed
March 23, 2026
Annual meeting
May 8, 2026
Pay year
2025
Named executives
5
CEO total pay
$32.5M+76% vs prior year
CEO to median employee
192:1
CEO pay in equity
51%$16.5M in awards
Prior say-on-pay support
93%of votes cast
Total Net Revenues
$61.2BN8.5% operational growth versus 2024
Operating Cash Flow
$19.0BNGenerated in 2025
Growth Platform Net Revenues
$56.6BN19.6% increase compared to 2024
Say on Pay Support
93.1%From 2025 annual meeting

How Michael was paid

$32.5M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary5%Stock awards41%Option awards10%Non-equity incentive16%Pension and deferred comp27%All other compensation2%

Named executive officers

ExecutiveTotal
Robert A. MichaelChairman of the Board and Chief Executive Officer$32,530,984
Scott T. ReentsExecutive Vice President, Chief Financial Officer$12,353,002
Jeffrey R. StewartExecutive Vice President, Chief Commercial Officer$15,435,304
Azita Saleki-GerhardtExecutive Vice President, Chief Operations Officer$10,791,976
Roopal B. ThakkarExecutive Vice President, Research & Development and Chief Scientific Officer$9,912,843

What changed and why

  • $61.2BTotal net revenues reached $61.2 billion, reflecting 8.5% operational growth compared to 2024.
  • $32.5MCEO total compensation was $32,530,984 for fiscal 2025 following his promotion to Chairman and CEO.
  • $56.6BGrowth Platform net revenues increased 19.6% to $56.6 billion, driven by double-digit sales growth for nine key assets.
  • 93.1%Stockholders expressed strong support for executive compensation with 93.1% approval at the 2025 annual meeting.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.